Cell and gene therapy has been saved
Cell and gene therapy
Opportunities and challenges to personalized medicine
Cell, gene, and other emerging therapies are distinctly different from traditional biopharma products. How can life sciences companies address challenges along key stages of the product life cycle?
- Growth in cell and gene therapy
- Read our three-part series of strategic insights for cell and gene therapy (CGT) CxOs and senior executives
- Read our latest insights
- Our cell and gene experience across the value chain
- Get in touch
Growth in cell and gene therapy
Cell and gene therapies (CGTs) have quickly emerged as one of the most transformative innovations in biopharmaceuticals in recent times. CGTs are being tested in therapeutic areas beyond their initial oncology focus to include neurology, ophthalmology, and COVID-19 treatment. With more than 900 firms globally focused on these advanced therapies and over 1,000 cell and/or gene therapy clinical trials currently underway, the industry could see a tsunami of approvals1 - experts predict within 10 years up to 60 new CGTs could be launched, treating about 350,000 patients in the United States alone2.
Despite all this clinical and commercial promise, as with any new and innovative disruptive technology, cell and gene therapy developers face challenges along several key dimensions—enabling patient access, managing supply chain and manufacturing operations, and developing a health care provider network.
Read our three-part series of strategic insights for cell and gene therapy (CGT) CxOs and senior executives
Why elevating responsibility to the c-suite can help avoid manufacturing missteps
Designing a patient-centric digital ecosystem
Your operating model needs to be as innovative as your science
Read our latest insights
Our cell and gene experience across the value chain
1 Commissioner of Food and Drugs - Food and Drug Administration Scott Gottlieb M.D., “Evaluation and research on new policies to advance development of safe and effective cell and gene therapies,” US FDA, press release, January 15, 2019.
What analysis may reveal about potential tax risks in an era of tax reform
Racing to keep up with robotic process automation in life sciences